BMO Capital raised the firm’s price target on Y-mAbs Therapeutics to $26 from $16 and keeps an Outperform rating on the shares. The company reported a “good” Q4 earnings print, and the firm’s increased price target reflects updated Danyelza net present value to $17 per share from $9 prior, primarily on lower operating expense for the drug given the current spend trajectory, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on YMAB:
- Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
- Y-Mabs Therapeutics Welcomes New Board Member, Dr. Tagliaferri
- Y-mAbs Therapeutics sees FY24 revenue $95M-$100M, consensus $96.27M
- Y-mAbs Therapeutics reports Q4 EPS (2c), consensus (20c)
- Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
